RBC Capital Remains Sidelined as Valeant Pharma (VRX) Announces Credit Amendment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
T. Rowe Price Sues Valeant Pharma (VRX) Alleging 'Fraudulent Scheme' That Cost Investors Billions - DJ
August 18, 2016 10:56 AM EDTT. Rowe Price Sues Valeant Pharma (NYSE: VRX) Alleging 'Fraudulent Scheme' That Cost Investors Billions - DJ
... MorePre-Open Stock Movers 8/18: (SEMI) (CIE) (RPTP) Higher; (EARS) (CERU) (PTLA) Lower
August 18, 2016 9:25 AM EDTAuris Medical Holding AG (Nasdaq: EARS) 64.1% LOWER; announced top-line results from the Phase 3 TACTT2 trial with Keyzilen (AM-101) in acute inner ear tinnitus. The TACTT2 trial did not meet the two co-primary efficacy endpoints of statistically significant changes in tinnitus loudness and tinnitus burden compared to placebo. Data from the TACTT2 trial support the positive safety profile established in previous studies, and results from the second Phase 3 trial, TACTT3, are expected in the fourth quarter of 2016.
Valeant amends credit facility for second time in six months
August 18, 2016 8:37 AM EDT(Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said its lenders had approved an amendment to its credit facility, giving the drugmaker more flexibility to sell assets and repay loans by taking on other debt.
The embattled... More
Valeant Pharma (VRX) Announces Lender Consent for Credit Facility Amendment
August 18, 2016 8:01 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it has obtained the requisite lender approval for an amendment to its credit facility. The Company expects to close the amendment next week, subject to customary closing conditions. The amendment will:
reduce the interest... More
Wall St. inches up with energy gain, Wal-Mart
August 18, 2016 7:32 AM EDTBy Caroline Valetkevitch
NEW YORK (Reuters) - U.S. stocks ended up slightly on Thursday as Brent oil's rise above $50 a barrel boosted energy shares and an upbeat outlook lifted Wal-Mart (NYSE: WMT) to a 14-month high.
Wal-Mart rose 1.9 percent to end at $74.30 after the retailer reported a better-than-expected quarterly profit and raised its fiscal-year outlook. The upbeat forecast followed disappointing outlooks from Target (NYSE: TGT) and Lowe's Companies (NYSE: LOW) the previous day.
The energy index jumped 1.8... More
Valeant Pharma (VRX) Ramps to Session Highs Following Analyst Upgrade
August 17, 2016 12:00 PM EDTValeant Pharma (NYSE: VRX) shares are reaching new session highs midday Wednesday. The stock is up well over 13 percent with high volume.
Notably, Morgan Stanley upgraded the stock earlier. For more color on the call, click here.
... MoreNotable Analyst Rating Changes 8/17: (INFO) (AVXS) (VRX) Upgraded; (ADS) (CUZ) (ASML) Downgraded
August 17, 2016 10:12 AM EDTUPGRADES
Piper Jaffray upgrades IHS Markit (Nasdaq: INFO) from Neutral to Overweight with a price target of $43.... More
Pre-Open Stock Movers 8/17: (SKYS) (SCYX) (NVIV) Higher; (STEM) ((JASO) (CREE) Lower
August 17, 2016 9:27 AM EDTSky Solar Holdings, Ltd. (Nasdaq: SKYS) 34.9% HIGHER; announced that the Company entered into a Letter of Intent with Solar Partnership Capital Ltd (Solar Partnership or SPC), a non-affiliate of the Company in certain Japanese projects, pursuant to which Solar Partnership confirmed its intention to acquire interests it currently does not own in 152 MW of solar projects from Sky Solar Japan K.K. (SSJ) and to take on certain specified liabilities associated with respect to those projects (the Transaction Assets) for a total purchase price of JPY17 billion (approximately $US165 million), subject to certain... More
Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley
August 17, 2016 7:03 AM EDTValeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanleys upgrade to Overweight and raising its price target to $42 from $33.
... MoreMorgan Stanley Makes Bullish Call on Valeant (VRX); Rating Raised to 'Overweight'
August 17, 2016 6:59 AM EDT(Updated - August 17, 2016 10:46 AM EDT)
Morgan Stanley upgraded Valeant Pharmaceuticals (NYSE: VRX) from Equalweight to Overweight with a price target of $42, implying 58% upside. The stock's bull case price target is $68 and its bear case is $11. Analyst David Risinger said his upgrade was primarily a multiple expansion call.
Risinger explained, "Although VRX still faces risks, we see the upside skew as attractive. Risk of severe financial stress... More
